ArticleDrug design, development and therapy2022

Development of a Nanoliposomal Formulation of Erlotinib for Lung Cancer and in vitro/In vivo Antitumoral Evaluation [Retraction].

PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.